公开(公告)号：US10716878B2

公开(公告)日：2020-07-21

申请号：US14353286

申请日：2012-10-19

Applicant: The Regents of the University of California

Inventor： B. Chia Soo ,  Kang Ting ,  Zhong Zheng

IPC: A61L27/34 ,  A61L31/16 ,  A61L31/06 ,  A61L27/54 ,  A61C8/00 ,  A61L31/10 ,  A61F2/30 ,  A61F2/44

Abstract: Implant-associated bacterial infections are one of the most serious complications in orthopedic surgery. Treatment of these infections often requires multiple operations, device removal, long-term systemic antibiotics, and extended rehabilitation, and is frequently ineffective, leading to worse clinical outcomes and increased financial costs. Silver nanoparticle/poly(DL-lactic-co-glycolic acid) (PLGA)-coated stainless steel alloy (SNPSA) was evaluated as a potential antimicrobial implant material. It was found that SNPSA exhibited strong antibacterial activity in vitro and ex vivo, and promoted MC3T3-E1 pre-osteoblasts proliferation and maturation in vitro. Furthermore, SNPSA implants induced osteogenesis while suppressing bacterial survival in contaminated rat femoral canals. The results indicate that SNPSA has simultaneous antimicrobial and osteoinductive properties that make it a promising therapeutic material in orthopedic surgery.

公开(公告)号：US09744214B2

公开(公告)日：2017-08-29

申请号：US14106617

申请日：2013-12-13

Applicant: The Regents of the University of California

Inventor： B. Chia Soo ,  Kang Ting ,  Zhong Zheng

IPC: A61K38/17 ,  A61K38/18

CPC classification number: A61K38/1841 ,  A61K38/17 ,  A61K38/1709 ,  A61K2300/00

Abstract: The present invention discloses methods and compositions for treating or ameliorating a condition associated with increased or decreased myofibroblast activities and use thereof.

公开(公告)号：US20160271186A1

公开(公告)日：2016-09-22

申请号：US15090443

申请日：2016-04-04

Applicant: The Regents of the University of California

Inventor： B. Chia Soo ,  Kang Ting ,  Bruno M. Peault

IPC: A61K35/545 ,  C12N5/077 ,  A61L31/16 ,  C12N5/074 ,  A61L31/08

Abstract: Embodiments of the present invention provide a population of purified perivascular stem cells (PSC) or induced pluripotent stem cells (iPS) and a supernatant of stem cell free from the stem cell, a composition comprising any of these, and a method of using and making them.

公开(公告)号：US12144843B2

公开(公告)日：2024-11-19

申请号：US16928724

申请日：2020-07-14

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： B. Chia Soo ,  Kang Ting ,  Zhong Zheng

IPC: A61K38/18 ,  A61K38/17

Abstract: The present invention discloses methods and compositions for treating or ameliorating a condition associated with increased or decreased myofibroblast activities and use thereof.

公开(公告)号：US11000570B2

公开(公告)日：2021-05-11

申请号：US15954225

申请日：2018-04-16

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Kang Ting ,  B. Chia Soo

IPC: A61K38/17 ,  C07K14/47 ,  A61K35/32 ,  A61M37/00 ,  A61N1/30

Abstract: This application is drawn to a method of using an isoform NELL-1 peptide, and compositions thereof for bone formation or for treating, preventing, or ameliorating osteoporosis.

公开(公告)号：US10729747B2

公开(公告)日：2020-08-04

申请号：US16405782

申请日：2019-05-07

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： B. Chia Soo ,  Kang Ting ,  Zhong Zheng

IPC: A61K38/18 ,  A61K38/17

Abstract: The present invention discloses methods and compositions for treating or ameliorating a condition associated with increased or decreased myofibroblast activities and use thereof.

公开(公告)号：US10675307B2

公开(公告)日：2020-06-09

申请号：US15090443

申请日：2016-04-04

Applicant: The Regents of the University of California

Inventor： B. Chia Soo ,  Kang Ting ,  Bruno M. Peault

IPC: A61K38/00 ,  A61K35/545 ,  A61K38/17 ,  C12N5/0775 ,  A61K35/12 ,  A61L31/08 ,  A61L31/16 ,  C12N5/074 ,  C12N5/077

Abstract: Embodiments of the present invention provide a population of purified perivascular stem cells (PSC) or induced pluripotent stem cells (iPS) and a supernatant of stem cell free from the stem cell, a composition comprising any of these, and a method of using and making them.

公开(公告)号：US20230002738A1

公开(公告)日：2023-01-05

申请号：US17679745

申请日：2022-02-24

Applicant: The Regents of The University of California

Inventor： B. Chia Soo ,  Kang Ting ,  Zhong Zheng

IPC: C12N5/074 ,  A61K35/12

Abstract: The present invention provides a method of treating a disorder using a fibromodulin (FMOD) reprogrammed (FReP) cell. The method comprises administering locally to a human being the FReP cell to a site in need thereof of the human being.

公开(公告)号：US10279010B2

公开(公告)日：2019-05-07

申请号：US15673880

申请日：2017-08-10

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： B. Chia Soo ,  Kang Ting ,  Zhong Zheng

IPC: A61K38/18 ,  A61K38/17

Abstract: The present invention discloses methods and compositions for treating or ameliorating a condition associated with increased or decreased myofibroblast activities and use thereof.

公开(公告)号：US09885014B2

公开(公告)日：2018-02-06

申请号：US13677186

申请日：2012-11-14

Applicant: The Regents of the University of California

Inventor： Kang Ting ,  B. Chia Soo ,  Zhong Zheng

IPC: C12N5/00 ,  A61K35/545 ,  C12N5/074

CPC classification number: C12N5/0018 ,  A61K35/545 ,  C12N5/0696 ,  C12N2501/998

Abstract: The present invention provides pluripotent stem cell like (PSCL) cells or clones, a culture medium therefore, and a supernatant thereof, and methods of making and using the same.